Physician profile
Forrest G Ringold
NPI 1881612786
$677,634.29
in general payments reported to CMS, 2019-2025
27 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $92K · 2021: $112K · 2022: $99K · 2023: $117K · 2024: $98K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $137K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $41K · Consulting Fee: $22K · Food and Beverage: $8,271 · Acquisitions: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $137,350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,425.00 |
| Travel and Lodging | $40,655.40 |
| Consulting Fee | $21,550.00 |
| Food and Beverage | $8,270.59 |
| Acquisitions | $1,665.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $496,454.72 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Teleflex LLC | $97,682.17 | 2022-2025 | Titan Sgs, Titan Sgs Standard Gastric Stapler, Titan Sgs Bailout Chuck |
| Standard Bariatrics, INC. | $65,101.84 | 2021-2023 | Titan Sgs Standard Gastric Stapler |
| Suture Ease, INC. | $6,750.00 | 2023-2024 | |
| New Wave Endo-Surgical Corp. | $4,000.00 | 2025 | |
| Medtronic, INC. | $2,744.15 | 2021-2024 | Signia, Ligasure, Endoflip |
| Organogenesis INC. | $1,466.27 | 2022 | |
| Medical Device Business Services, INC. | $1,054.72 | 2019 | |
| Enterra Medical, INC. | $1,037.18 | 2025 | |
| Novo Nordisk INC | $387.77 | 2024-2025 | Wegovy |
| Baxter Healthcare | $221.84 | 2019-2025 | Perclot |
| W. L. Gore & Associates, INC. | $186.34 | 2019 | |
| Covidien LP | $168.48 | 2019-2020 | |
| Tela Bio, INC. | $79.27 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Ethicon US, LLC | $74.88 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2023 | Gattex |
| Dilon Technologies, INC. | $25.71 | 2025 | Hemoblast Bellows |
| Integra Lifesciences Corporation | $24.19 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Endogastric Solutions, INC | $24.12 | 2023 | Esophyx |
| Vertex Pharmaceuticals Incorporated | $20.42 | 2025 | |
| Polynovo North America LLC | $17.90 | 2022 | |
| Csl Behring | $15.68 | 2019 | |
| Kerecis Limited | $14.97 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Intra-Sana Laboratories | $14.24 | 2024 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Allergan, INC. | $13.99 | 2019 | |
| Redhill Biopharma INC. | $13.70 | 2021 | |
| Davol INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$18,068.06 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Ringold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.